Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Century Therapeutics, Inc. - Common Stock
(NQ:
IPSC
)
1.370
-0.130 (-8.67%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Century Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday
↗
March 24, 2025
Via
Benzinga
Demystifying Century Therapeutics: Insights From 4 Analyst Reviews
↗
March 21, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
March 19, 2025
Via
Benzinga
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
March 19, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
4 Analysts Have This To Say About Century Therapeutics
↗
January 22, 2025
Via
Benzinga
5 Analysts Assess Century Therapeutics: What You Need To Know
↗
June 04, 2024
Via
Benzinga
Century Therapeutics: Q4 Earnings Insights
↗
March 14, 2024
Via
Benzinga
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
January 21, 2025
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%
↗
November 28, 2024
Via
Benzinga
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 05, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
November 04, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 03, 2024
Via
Benzinga
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
September 26, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
↗
August 15, 2024
Via
Benzinga
IPSC Stock Earnings: Century Therapeutics Beats EPS for Q2 2024
↗
August 08, 2024
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
June 03, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
May 10, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024
↗
May 09, 2024
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 23, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
↗
April 11, 2024
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D...
Via
Benzinga
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
April 11, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 19, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023
↗
March 14, 2024
IPSC stock results show that Century Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
March 14, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
